AAPL294.30-2.71 (-0.91%) ▼|ABBV234.76+4.75 (+2.07%) ▲|ABT90.53+2.70 (+3.07%) ▲|ACN127.01+2.18 (+1.75%) ▲|ADBE197.43+2.53 (+1.30%) ▲|AMAT585.88-54.30 (-8.48%) ▼|AMD519.85-31.78 (-5.76%) ▼|AMGN347.01+2.29 (+0.66%) ▲|AMT179.38+2.95 (+1.67%) ▲|AMZN234.11+1.32 (+0.57%) ▲|AVGO380.15-11.98 (-3.06%) ▼|AXP337.78-0.29 (-0.09%) ▼|BA216.71-4.12 (-1.87%) ▼|BAC57.91+0.54 (+0.94%) ▲|BKNG168.94+1.17 (+0.70%) ▲|BLK1,015.33-36.41 (-3.46%) ▼|BMY55.53+0.83 (+1.52%) ▲|BNY147.29+0.85 (+0.58%) ▲|BRK-B492.81+4.12 (+0.84%) ▲|C144.97-0.70 (-0.48%) ▼|CAT984.24-38.04 (-3.72%) ▼|CL91.43+2.76 (+3.11%) ▲|CMCSA22.80+0.48 (+2.15%) ▲|COF197.81-2.89 (-1.44%) ▼|COP109.97+0.27 (+0.25%) ▲|COST957.68+6.33 (+0.67%) ▲|CRM153.42+3.30 (+2.20%) ▲|CSCO121.15-0.38 (-0.31%) ▼|CVS101.57+0.27 (+0.27%) ▲|CVX175.98+0.92 (+0.53%) ▲|DE591.94-6.65 (-1.11%) ▼|DHR178.97+0.78 (+0.44%) ▲|DIS103.53+1.08 (+1.05%) ▲|DUK125.05+1.53 (+1.24%) ▲|EMR143.14-7.07 (-4.71%) ▼|FDX317.24-11.54 (-3.51%) ▼|GD350.34+6.98 (+2.03%) ▲|GE356.47+1.35 (+0.38%) ▲|GEV1,034.98-92.61 (-8.21%) ▼|GILD125.05+0.18 (+0.14%) ▲|GM78.95-1.48 (-1.84%) ▼|GOOG346.08-2.70 (-0.77%) ▼|GOOGL346.13-3.43 (-0.98%) ▼|GS1,094.44-11.93 (-1.08%) ▼|HD324.45-2.17 (-0.66%) ▼|HON222.37-5.74 (-2.52%) ▼|IBM264.94+12.72 (+5.04%) ▲|INTC132.28-8.66 (-6.14%) ▼|INTU258.05+0.28 (+0.11%) ▲|ISRG403.18+0.23 (+0.06%) ▲|JNJ239.08+7.79 (+3.37%) ▲|JPM334.14+2.66 (+0.80%) ▲|KO80.31+0.78 (+0.98%) ▲|LIN512.26-4.45 (-0.86%) ▼|LLY1,107.08+5.00 (+0.45%) ▲|LMT503.67+10.07 (+2.04%) ▲|LOW213.54-0.86 (-0.40%) ▼|LRCX371.33-38.21 (-9.33%) ▼|MA488.07+3.98 (+0.82%) ▲|MCD271.66+1.56 (+0.58%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.63+1.36 (+1.72%) ▲|META562.20-1.65 (-0.29%) ▼|MMM161.84-1.38 (-0.85%) ▼|MO71.61+2.10 (+3.02%) ▲|MRK119.60+4.12 (+3.57%) ▲|MS226.03-1.06 (-0.47%) ▼|MSFT373.94+6.60 (+1.80%) ▲|MU1,051.77-159.61 (-13.18%) ▼|NEE86.43+0.35 (+0.41%) ▲|NFLX72.82-0.06 (-0.08%) ▼|NKE42.38-0.81 (-1.88%) ▼|NOW95.94+2.93 (+3.15%) ▲|NVDA200.04-8.61 (-4.13%) ▼|ORCL165.16-9.91 (-5.66%) ▼|PEP142.05+1.34 (+0.95%) ▲|PFE24.72-0.36 (-1.44%) ▼|PG150.86+3.18 (+2.15%) ▲|PLTR116.70-2.80 (-2.34%) ▼|PM178.69+5.52 (+3.19%) ▲|QCOM204.13-17.77 (-8.01%) ▼|RTX186.39+4.56 (+2.51%) ▲|SBUX101.05+0.90 (+0.90%) ▲|SCHW93.17+1.14 (+1.24%) ▲|SO94.93+1.50 (+1.61%) ▲|SPG216.74+2.17 (+1.01%) ▲|T22.81+0.71 (+3.21%) ▲|TMO469.35+5.34 (+1.15%) ▲|TMUS184.57+4.51 (+2.50%) ▲|TSLA381.61-23.44 (-5.79%) ▼|TXN304.36-27.92 (-8.40%) ▼|UBER69.67-1.76 (-2.46%) ▼|UNH409.25+2.57 (+0.63%) ▲|UNP258.61-1.30 (-0.50%) ▼|UPS105.83-1.41 (-1.31%) ▼|USB60.05+1.37 (+2.33%) ▲|V328.48+1.88 (+0.58%) ▲|VZ46.73+1.37 (+3.02%) ▲|WFC84.13+0.29 (+0.35%) ▲|WMT119.42+2.24 (+1.91%) ▲|XOM139.73+1.26 (+0.91%) ▲|AAPL294.30-2.71 (-0.91%) ▼|ABBV234.76+4.75 (+2.07%) ▲|ABT90.53+2.70 (+3.07%) ▲|ACN127.01+2.18 (+1.75%) ▲|ADBE197.43+2.53 (+1.30%) ▲|AMAT585.88-54.30 (-8.48%) ▼|AMD519.85-31.78 (-5.76%) ▼|AMGN347.01+2.29 (+0.66%) ▲|AMT179.38+2.95 (+1.67%) ▲|AMZN234.11+1.32 (+0.57%) ▲|AVGO380.15-11.98 (-3.06%) ▼|AXP337.78-0.29 (-0.09%) ▼|BA216.71-4.12 (-1.87%) ▼|BAC57.91+0.54 (+0.94%) ▲|BKNG168.94+1.17 (+0.70%) ▲|BLK1,015.33-36.41 (-3.46%) ▼|BMY55.53+0.83 (+1.52%) ▲|BNY147.29+0.85 (+0.58%) ▲|BRK-B492.81+4.12 (+0.84%) ▲|C144.97-0.70 (-0.48%) ▼|CAT984.24-38.04 (-3.72%) ▼|CL91.43+2.76 (+3.11%) ▲|CMCSA22.80+0.48 (+2.15%) ▲|COF197.81-2.89 (-1.44%) ▼|COP109.97+0.27 (+0.25%) ▲|COST957.68+6.33 (+0.67%) ▲|CRM153.42+3.30 (+2.20%) ▲|CSCO121.15-0.38 (-0.31%) ▼|CVS101.57+0.27 (+0.27%) ▲|CVX175.98+0.92 (+0.53%) ▲|DE591.94-6.65 (-1.11%) ▼|DHR178.97+0.78 (+0.44%) ▲|DIS103.53+1.08 (+1.05%) ▲|DUK125.05+1.53 (+1.24%) ▲|EMR143.14-7.07 (-4.71%) ▼|FDX317.24-11.54 (-3.51%) ▼|GD350.34+6.98 (+2.03%) ▲|GE356.47+1.35 (+0.38%) ▲|GEV1,034.98-92.61 (-8.21%) ▼|GILD125.05+0.18 (+0.14%) ▲|GM78.95-1.48 (-1.84%) ▼|GOOG346.08-2.70 (-0.77%) ▼|GOOGL346.13-3.43 (-0.98%) ▼|GS1,094.44-11.93 (-1.08%) ▼|HD324.45-2.17 (-0.66%) ▼|HON222.37-5.74 (-2.52%) ▼|IBM264.94+12.72 (+5.04%) ▲|INTC132.28-8.66 (-6.14%) ▼|INTU258.05+0.28 (+0.11%) ▲|ISRG403.18+0.23 (+0.06%) ▲|JNJ239.08+7.79 (+3.37%) ▲|JPM334.14+2.66 (+0.80%) ▲|KO80.31+0.78 (+0.98%) ▲|LIN512.26-4.45 (-0.86%) ▼|LLY1,107.08+5.00 (+0.45%) ▲|LMT503.67+10.07 (+2.04%) ▲|LOW213.54-0.86 (-0.40%) ▼|LRCX371.33-38.21 (-9.33%) ▼|MA488.07+3.98 (+0.82%) ▲|MCD271.66+1.56 (+0.58%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.63+1.36 (+1.72%) ▲|META562.20-1.65 (-0.29%) ▼|MMM161.84-1.38 (-0.85%) ▼|MO71.61+2.10 (+3.02%) ▲|MRK119.60+4.12 (+3.57%) ▲|MS226.03-1.06 (-0.47%) ▼|MSFT373.94+6.60 (+1.80%) ▲|MU1,051.77-159.61 (-13.18%) ▼|NEE86.43+0.35 (+0.41%) ▲|NFLX72.82-0.06 (-0.08%) ▼|NKE42.38-0.81 (-1.88%) ▼|NOW95.94+2.93 (+3.15%) ▲|NVDA200.04-8.61 (-4.13%) ▼|ORCL165.16-9.91 (-5.66%) ▼|PEP142.05+1.34 (+0.95%) ▲|PFE24.72-0.36 (-1.44%) ▼|PG150.86+3.18 (+2.15%) ▲|PLTR116.70-2.80 (-2.34%) ▼|PM178.69+5.52 (+3.19%) ▲|QCOM204.13-17.77 (-8.01%) ▼|RTX186.39+4.56 (+2.51%) ▲|SBUX101.05+0.90 (+0.90%) ▲|SCHW93.17+1.14 (+1.24%) ▲|SO94.93+1.50 (+1.61%) ▲|SPG216.74+2.17 (+1.01%) ▲|T22.81+0.71 (+3.21%) ▲|TMO469.35+5.34 (+1.15%) ▲|TMUS184.57+4.51 (+2.50%) ▲|TSLA381.61-23.44 (-5.79%) ▼|TXN304.36-27.92 (-8.40%) ▼|UBER69.67-1.76 (-2.46%) ▼|UNH409.25+2.57 (+0.63%) ▲|UNP258.61-1.30 (-0.50%) ▼|UPS105.83-1.41 (-1.31%) ▼|USB60.05+1.37 (+2.33%) ▲|V328.48+1.88 (+0.58%) ▲|VZ46.73+1.37 (+3.02%) ▲|WFC84.13+0.29 (+0.35%) ▲|WMT119.42+2.24 (+1.91%) ▲|XOM139.73+1.26 (+0.91%) ▲|
18.5 C
New York
Wednesday, June 24, 2026

Tag: treatments

newssourceFORcompanyinformationcontent1marketreleases

Participation in “The 113th Congress of Japan Society of Aesthetic Surgery,” May 2025

～Record Participation for SBC Medical. 22 doctors Present Insights in Their Respective Fields～ 
～Record Participation for SBC Medical. 22 doctors Present Insights in Their Respective Fields～

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round.

WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets

SHANGHAI, June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies...

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

CAESAREA, Israel, June 18, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical...

Chronic Hepatitis B Market–The US to Have the Lion’s Share Among the 7MM, Predicts DelveInsight

The chronic hepatitis B market size is predicted to surge owing to the increasing prevalence of the disease globally and rising awareness about early...

Applied Therapeutics Announces Key Leadership Appointments

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced key appointments to its executive leadership team with the promotions of Evan Bailey, MD, to Chief Medical Officer (CMO), effective June 15, 2025, and Dottie Caplan to Executive Vice President (EVP), Patient Advocacy and Government Affairs.

Genomics announces next stage of global roll-out of its predictive clinical tool Health Insights – the first ever UKCA-marked and MHRA registered test that...

Health Insights UK is Genomics' predictive clinical tool. It provides genetic risk testing as a secure, end-to-end solution based on a saliva sample that...

BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.

Solve M.E. Selects Simmaron Research As Recipient of ME/CFS Catalyst Award to Accelerate Low-Dose Rapamycin Trial for ME/CFS, Long COVID, and IACCs

The Catalyst Award will expedite the hunt for a validated test-to-treat model for ME/CFS, a disease for which there is currently no FDA-approved treatment. LOS...

Calviri Publishes Results Demonstrating Sensitive Detection of Stage 1 Tumors in Dogs

PHOENIX, June 17, 2025 /PRNewswire/ -- Calviri, Inc, a company focused on ending cancer in dogs and people, announces the publication of High-sensitivity multicancer...

Medical Biomimetics Market Share Set to Cross $55.36 Billion by 2030 with 7.6% CAGR- Exclusive Study by The Research Insights

CHICAGO, June 17, 2025 /PRNewswire/ -- The Global Medical Biomimetics Market is projected to be valued at USD 35.68 billion in 2024 and reach USD 55.36 billion by 2030, growing...

Lung Cancer Research Foundation Announces Request for Proposals Focused on Curing EGFR Mutant Lung Cancers

New Team Science Award is $1.5 million Over Three Years NEW YORK, June 17, 2025 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) announces today...

Lung Cancer Research Foundation Announces New Research Collaboration with Boehringer Ingelheim

$2.25 Million Research Collaboration Focused on Understanding and Treating Lung Cancers Harboring HER2 Mutations; call for Requests for Proposals NEW YORK, June 17, 2025 /PRNewswire/...

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers